CLASS ACTION REMINDER: Berger Montague Advises Mereo BioPharma Group PLC (MREO) Investors to Inquire About a Securities Fraud Lawsuit by April 6, 2026

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased American Depositary Shares during the specified Class Period, highlighting potential misrepresentation regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo securities from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Company Background - Mereo BioPharma is a biopharmaceutical company based in London, UK, focusing on therapies for rare and serious diseases [2]. Group 3: Clinical Trials and Impact - Throughout the Class Period, Mereo made positive statements regarding the ORBIT and COSMIC Phase 3 programs, which were clinical trials for setrusumab aimed at treating Osteogenesis Imperfecta [3]. - On December 29, 2025, Mereo disclosed that neither clinical trial achieved its primary endpoint, leading to a significant drop in the price of its ADS by over 87%, from $2.31 to $0.29 per share [4].